OncoTargets and Therapy

Scope & Guideline

Elevating the discourse in oncology and therapeutics.

Introduction

Delve into the academic richness of OncoTargets and Therapy with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1178-6930
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessYes
CountryNew Zealand
TypeJournal
Convergefrom 2009 to 2024
AbbreviationONCOTARGETS THER / OncoTargets Ther.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

OncoTargets and Therapy is a journal dedicated to the dissemination of research focused on cancer treatment and therapy, emphasizing innovative approaches in oncology. The journal aims to provide a platform for original research, reviews, and case studies that advance the understanding of cancer biology and therapy.
  1. Cancer Therapeutics:
    The journal focuses on the development and evaluation of novel therapeutic strategies for various cancers, including chemotherapy, targeted therapy, immunotherapy, and combination therapies.
  2. Molecular Mechanisms of Cancer:
    Research articles often explore the underlying molecular and cellular mechanisms that contribute to cancer development, progression, and treatment resistance, with a particular emphasis on signaling pathways and gene expression.
  3. Biomarkers and Prognostic Indicators:
    The identification and validation of biomarkers for cancer diagnosis, prognosis, and treatment response are central themes, helping to personalize therapy and improve patient outcomes.
  4. Clinical Case Studies:
    The journal publishes clinical case reports that highlight unique therapeutic responses, novel treatment applications, and insights into cancer management, contributing to the clinical understanding of oncology.
  5. Translational Research:
    OncoTargets and Therapy promotes translational research that bridges the gap between laboratory findings and clinical applications, facilitating the development of new diagnostic and therapeutic strategies.
OncoTargets and Therapy has seen the emergence of several trending themes reflecting advancements in cancer research and treatment methodologies. These trends indicate a shift towards more innovative and personalized approaches to oncology.
  1. Immunotherapy Advances:
    The increasing focus on immunotherapy, particularly checkpoint inhibitors and CAR-T cell therapies, reflects the growing recognition of the immune system's role in cancer treatment and the need for novel immunotherapeutic strategies.
  2. Targeted Therapy Innovations:
    Research on targeted therapies, especially those targeting specific genetic mutations (e.g., EGFR, ALK), has surged, demonstrating a trend towards precision medicine in oncology.
  3. Long Non-Coding RNAs (lncRNAs):
    There is a rising interest in the role of lncRNAs in cancer biology, particularly their involvement in tumor progression, metastasis, and chemoresistance, highlighting their potential as therapeutic targets.
  4. Circular RNAs in Cancer:
    The exploration of circular RNAs as regulatory molecules in cancer has gained momentum, with studies investigating their roles in tumorigenesis and potential as biomarkers or therapeutic targets.
  5. Liquid Biopsy Techniques:
    Emerging research on liquid biopsies for cancer detection and monitoring reflects a trend towards non-invasive methods for assessing tumor dynamics and treatment response, paving the way for more personalized patient management.

Declining or Waning

While OncoTargets and Therapy has maintained a robust focus on various aspects of cancer therapy, some themes appear to be declining in prominence. This shift may reflect changes in research priorities or emerging trends in oncology.
  1. Traditional Chemotherapy Focus:
    The emphasis on traditional chemotherapy regimens has diminished as newer targeted therapies and immunotherapies have gained prominence, leading to a reduced number of studies centered on conventional chemotherapy.
  2. Single-Agent Therapies:
    There is a noticeable decline in research focusing solely on single-agent therapies, as the trend has shifted towards combination therapies that leverage synergistic effects for improved efficacy.
  3. Basic Science Research Without Clinical Application:
    Papers that focus purely on basic biological mechanisms without direct clinical implications or translational relevance appear to be less frequent, as the journal increasingly prioritizes research with clear applications to patient care.
  4. Epidemiological Studies:
    The number of epidemiological studies related to cancer has decreased, possibly due to a shift towards more molecular and targeted approaches in cancer research.
  5. Focus on Rare Cancers:
    Research focusing on rare cancers, while still important, has seen a reduction in publication frequency as the journal emphasizes more common malignancies that have larger patient populations and treatment implications.

Similar Journals

NEOPLASMA

Shaping the Future of Cancer Science
Publisher: AEPRESS SROISSN: 0028-2685Frequency: 6 issues/year

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

Cancer Drug Resistance

Unraveling the Mysteries of Drug Resistance in Cancer.
Publisher: OAE PUBLISHING INCISSN: Frequency: 1 issue/year

Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

MOLECULAR CARCINOGENESIS

Decoding the Pathways of Cancer Development
Publisher: WILEYISSN: 0899-1987Frequency: 12 issues/year

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

Molecular and Clinical Oncology

Innovating cancer care through rigorous research.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

International Journal of Cancer Management

Advancing cancer care through innovative research.
Publisher: BRIEFLANDISSN: 2538-4422Frequency: 12 issues/year

The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

CURRENT CANCER DRUG TARGETS

Exploring the latest breakthroughs in cancer drug targets.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Oncologie

Bridging theory and practice in cancer care.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

ONCOLOGY RESEARCH

Driving Progress in Cancer Treatment and Research
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

ANTI-CANCER DRUGS

Pioneering Discoveries in Oncology Pharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Journal of Cancer

Fostering collaboration to conquer cancer challenges.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.